Candidozyma auris, formerly referred to as Candida auris, has been identified as a swiftly spreading drug-resistant fungus posing a significant risk to individuals with compromised immune systems. Its ability to cause severe illnesses and even death is causing alarm in the healthcare sphere, particularly as its transmission continues to increase and outbreaks ramp up in severity. The European Center for Disease Prevention and Control (ECDC) has recently issued a warning, bringing to light the speed at which C. auris is proliferating within healthcare establishments across Europe, positioning it as an escalating danger to patient health.
The ECDC’s revelation underscores a growing concern; the number of cases is on the rise, outbreaks are escalating in size, and ongoing local transmission is being reported in multiple countries. Countries that have noted a particularly high incidence of cases over the past decade include Spain, Greece, Italy, Romania, and Germany. In 2023 alone, this relentless fungus was identified in 18 countries, triggering urgent calls from global health agencies for immediate action to curb its spread.
According to Dr. Diamantis Plachouras, who heads the Antimicrobial Resistance and Healthcare-Associated Infections section at the ECDC, C. auris has expanded its reach from isolated cases to widespread prevalence in certain countries in just a few years, revealing its rapid colonization capability within hospital environments. However, Dr. Plachouras urges that this distressing scenario is not inevitable – early detection coupled with prompt, coordinated infection control efforts hold the potential to thwart further propagation of C. auris.
In the United States, the Centers for Disease Control and Prevention (CDC) recorded a total of 10,788 clinical cases from 2016 to 2023. Areas most significantly affected were New York, Florida, California, Nevada, and Illinois. The first reported C. auris case on American soil came in 2013 when a 61-year-old female patient was brought to New York from the United Arab Emirates. Unfortunately, she passed away within a week. The CDC emphasizes early identification as essential in managing C. auris, although treatment is often complicated due to its high drug resistance. Over 90% of C. auris infections are reportedly resistant to at least one type of drug. Furthermore, individuals of any age can become affected by C. auris; however, those who have been hospitalized long-term, particularly those with inserted lines and tubes, are considered most at risk.
Source: https://people.com/deadly-drug-resistant-fungus-is-sweeping-through-hospitals-11809182